Video

How Have High Cost Hepatitis C Drugs Impacted Specialty Pharmacy?

Author(s):

Davy James, Managing Editor

Ryan Nolan, PharmD, MBA, CSP, clinical services manager at Diplomat, discusses ongoing lessons from the market reaction to high cost hepatitis C treatments.

Ryan Nolan, PharmD, MBA, CSP, clinical services manager at Diplomat, discusses ongoing lessons from the market reaction to high cost hepatitis C treatments.

Related Videos
Image credit: JJAVA | stock.adobe.com
Related Content
Gene editing in chronic hepatitis B -- Image credit: 红 王 | stock.adobe.com
April 22nd 2025

PBGENE-HBV Granted FDA Fast Track Designation for Chronic Hepatitis B

Gillian McGovern, Associate Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Composition with pills of Bayer Aspirin
April 17th 2025

High-Dose Aspirin With IVIG Does Not Meaningfully Reduce Coronary Artery Lesions in Children With Kawasaki Disease

Luke Halpern, Assistant Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Gut health -- Image credit: sdecoret | stock.adobe.com
April 16th 2025

Essential Immune Cells in Intestine Cause Gut Inflammation, Allergic Responses to Foods When Absent

Gillian McGovern, Associate Editor
Microscopic View of Blood Cells Related to Aplastic Anemia
April 16th 2025

Allogeneic T Regulatory Cell Product CK0801 Granted FDA Orphan Drug Designation for Aplastic Anemia Treatment

Luke Halpern, Assistant Editor